Drug Trial Radar · NCT06916130
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A
Last checked: Nov 20, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Apr 21, 2025
Primary completion
Sep 1, 2025
Study completion Sep 1, 2025
Sponsor
- Lead sponsor
- Addpharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-120 in healthy subjects.
Conditions
- Gastroesophageal Reflux Disease (GERD)
Interventions
AD-120ADrug
Administered before the breakfast during 7 days, Oral, Tablet
AD-120Drug
Administered before the breakfast during 7 days, Oral, Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration-time curve over a dosing interval at steady state (AUCτ,ss)Time frame: AUCτ,ss: pre-dose to 24 hours of 1st administration versus pre-dose to 24 hours of repeated administration (7days)
- The time of peak concentration after single doseTime frame: Tmax: from pre-dose to 24 hours of 1st administration
- Percent decrease from baseline in integrated gastric acidity measured by 24h pH monitoringTime frame: 24 hours before 1st administration to 24 hours after repeated administration (7days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.